CEO Jan Mikkelsen highlighted 2024 as a pivotal year, with SKYTROFA achieving €200 million in revenue and a 6.5% share of the U.S. growth hormone market. The product now holds 45% of the U.S.

Trump's tariffs will not only impact sponsors, but higher costs will ripple down the clinical trial supply chain in the US.

GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.

If you're focused on delivering a high return on capital for your shareholders, you should consider M&A as an integral part ...